Residency · Residency · Urology
Neoadjuvant and Adjuvant Therapy for Muscle-Invasive Bladder Cancer
Overview
The management of muscle-invasive bladder cancer (MIBC) increasingly incorporates cisplatin-based neoadjuvant chemotherapy, immune checkpoint inhibitors such as adjuvant nivolumab and pembrolizumab, and emerging perioperative combination regimens. A critical component of this approach is the evaluation of pathologic response to guide subsequent treatment decisions.
Neoadjuvant Chemotherapy
Rationale
MIBC is characterized by a high incidence of occult micrometastatic disease at diagnosis, with approximately 50% of patients eventually developing distant metastases. Neoadjuvant chemotherapy aims to treat these micrometastases before surgical intervention. Compared to adjuvant therapy, neoadjuvant treatment offers several advantages: it benefits from better drug delivery due to intact tumor vasculature, allows in vivo assessment of chemosensitivity through pathologic response, and is generally better tolerated by patients prior to cystectomy than afterward. Importantly, level 1 evidence supports an overall survival (OS) benefit with neoadjuvant chemotherapy.
Evidence
Key trials have established the benefit of neoadjuvant chemotherapy in MIBC. The SWOG 8710 (INT-0080) trial compared methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) plus cystectomy versus cystectomy alone, demonstrating a median OS of 77 months versus 46 months, respectively, and a pathologic complete response (pT0) rate of 38% compared to 15%. The BA06 30894 meta-analysis, pooling data from 11 randomized controlled trials, showed a 5% absolute OS benefit at 5 years with cisplatin-based neoadjuvant chemotherapy. Similarly, the ABC Meta-analysis in 2005 confirmed a 5-6% absolute survival advantage with cisplatin-based neoadjuvant regimens. Achieving a pT0 status at cystectomy, indicating complete pathologic response, is the strongest predictor of long-term survival, with over 85% 5-year OS.
Standard Regimens
The two main cisplatin-based neoadjuvant chemotherapy regimens are dose-dense MVAC (ddMVAC) and gemcitabine plus cisplatin (GC). The ddMVAC regimen consists of methotrexate, vinblastine, doxorubicin, and cisplatin administered in four cycles every two weeks with granulocyte colony-stimulating factor (G-CSF) support. This regimen yields higher pathologic complete response rates than standard MVAC and is better tolerated, making it increasingly preferred over GC. The GC regimen involves four cycles every three weeks and offers similar efficacy with lower toxicity, making it the most widely used regimen. Both regimens require patients to be eligible for cisplatin.
| Regimen | Drugs | Cycles | Schedule | pT0 Rate | Key Points |
|---|---|---|---|---|---|
| ddMVAC | Methotrexate, vinblastine, doxorubicin, cisplatin | 4 | q2 weeks + G-CSF | 35-40% | Higher pCR than GC; increasingly preferred |
| GC | Gemcitabine, cisplatin | 4 | q3 weeks | ~25% | Most widely used; lower toxicity |
Cisplatin Eligibility Criteria
Eligibility for cisplatin-based chemotherapy generally requires a glomerular filtration rate (GFR) of at least 60 mL/min, although some clinicians may use a threshold of 50 mL/min with dose adjustments. Patients should have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 and no significant hearing loss, neuropathy, or heart failure. Approximately 30-50% of MIBC patients are ineligible for cisplatin due to comorbidities or renal insufficiency.
Cisplatin-Ineligible Patients
For patients who cannot receive cisplatin, there is no established neoadjuvant chemotherapy alternative with proven overall survival benefit. Carboplatin-based regimens are inferior and are not recommended as substitutes. Immune checkpoint inhibitors are currently under investigation in the neoadjuvant setting for cisplatin-ineligible patients. In the absence of effective alternatives, these patients typically proceed directly to cystectomy.
Neoadjuvant Duration
Neoadjuvant chemotherapy is typically administered over three to four cycles, with surgery ideally performed within four to eight weeks after completing chemotherapy. Delays beyond 12 weeks from diagnosis to cystectomy are associated with worse outcomes, so neoadjuvant therapy should not excessively postpone definitive surgery.
Pathologic Response Assessment
Complete Response (pT0)
Complete pathologic response, defined as no residual tumor in the cystectomy specimen (pT0), is achieved in 25-40% of patients receiving cisplatin-based neoadjuvant chemotherapy. This status correlates with a 5-year overall survival exceeding 85% and represents the strongest prognostic factor following cystectomy.
Partial Response (≤pT1N0)
Partial response involves downstaging to non-muscle-invasive disease or no residual disease (≤pT1N0). Patients with partial response also experience improved survival compared to those who do not respond to neoadjuvant therapy.
Non-Response (≥pT2)
Non-responders retain muscle-invasive disease (≥pT2) despite neoadjuvant treatment and have a poorer prognosis. For these patients, adjuvant immunotherapy with agents such as nivolumab should be considered. Approximately 40-50% of patients do not achieve significant downstaging after neoadjuvant chemotherapy.
Adjuvant Therapy
Adjuvant Chemotherapy
Adjuvant chemotherapy is indicated for patients who did not receive neoadjuvant chemotherapy and have adverse pathologic features, including pT3-T4 tumors, positive lymph nodes (pN+), or positive surgical margins. The evidence supporting adjuvant chemotherapy is less robust than for neoadjuvant therapy and is often complicated by post-surgical morbidity, delayed recovery, and renal function decline. For cisplatin-eligible patients who did not receive neoadjuvant therapy, adjuvant regimens such as GC or ddMVAC may be considered.
Adjuvant Nivolumab (CheckMate 274)
Nivolumab, an anti-PD-1 immune checkpoint inhibitor, has been shown in the CheckMate 274 trial to improve disease-free survival (DFS) in patients with high-risk MIBC (≥pT3 or pN+) following radical cystectomy. The trial demonstrated a DFS of 21 months with nivolumab versus 11 months with placebo in the intent-to-treat population, with greater benefit observed in tumors expressing PD-L1 ≥1%. Nivolumab is FDA-approved for adjuvant use after cystectomy in high-risk urothelial carcinoma and is administered for one year, either every two or four weeks. It is applicable to patients regardless of whether they received neoadjuvant cisplatin-based chemotherapy. Its key role is in patients who could not receive neoadjuvant therapy or who have residual disease (≥pT2) after neoadjuvant treatment.
Perioperative Immunotherapy (Emerging)
Neoadjuvant Checkpoint Inhibitors
Several trials are evaluating immune checkpoint inhibitors alone or in combination with chemotherapy in the neoadjuvant setting. The PURE-01 trial reported a 42% pathologic complete response rate with pembrolizumab in PD-L1-positive tumors. The ABACUS trial demonstrated a 31% pCR rate with neoadjuvant atezolizumab. The NIAGARA trial, a landmark phase 3 study, assessed durvalumab combined with GC neoadjuvant chemotherapy followed by adjuvant durvalumab, showing improved event-free survival compared to GC alone. The KEYNOTE-866 trial is investigating pembrolizumab plus GC neoadjuvant therapy, with results pending. CheckMate 901 is exploring nivolumab combined with GC in the perioperative setting.
NIAGARA Trial (Key Result)
The NIAGARA trial compared durvalumab plus GC neoadjuvant therapy followed by cystectomy and adjuvant durvalumab versus GC alone followed by cystectomy. It demonstrated significant improvements in event-free survival and pathologic complete response rates. This trial is practice-changing, as perioperative durvalumab plus GC is becoming a new standard for cisplatin-eligible MIBC, with FDA review anticipated or ongoing.
Erdafitinib and FGFR-Targeted Therapy
Approximately 15-20% of MIBC tumors harbor FGFR3 alterations. Erdafitinib, an FGFR inhibitor, is FDA-approved for metastatic urothelial carcinoma with FGFR2/3 alterations. Neoadjuvant FGFR-targeted therapies are currently under investigation.
Bladder-Sparing Trimodal Therapy (TMT)
Components
Trimodal therapy consists of maximal transurethral resection of bladder tumor (TURBT) aiming for visibly complete resection, concurrent chemoradiation using cisplatin or 5-fluorouracil with mitomycin C alongside 55-65 Gy of radiation, and re-evaluation cystoscopy with biopsy at mid-treatment.
Candidate Selection
Ideal candidates for TMT have a unifocal tumor less than 5 cm without carcinoma in situ (CIS) or hydronephrosis, have undergone complete TURBT with no visible tumor remaining, possess adequate bladder function, and prefer bladder preservation. Cisplatin eligibility is important as it serves as a radiosensitizer.
Outcomes
TMT achieves a 5-year overall survival of 50-60%, comparable to cystectomy in well-selected patients, with a 5-year intact bladder rate of 60-70%. Complete response at mid-treatment evaluation occurs in 70-80% of cases. However, salvage cystectomy is required in 20-30% of patients, and this procedure carries higher morbidity than upfront cystectomy.
Controversy
No randomized controlled trials have directly compared TMT to radical cystectomy. Selection bias exists in TMT series, favoring patients with more favorable tumors. While TMT outcomes may approach those of cystectomy in ideal candidates, cystectomy remains the gold standard for MIBC. Multidisciplinary discussion is essential to determine the best approach for each patient.
<image>A treatment algorithm flowchart for muscle-invasive bladder cancer showing the perioperative therapy decision pathway. Starting with MIBC diagnosis, branches to cisplatin-eligible (neoadjuvant GC or ddMVAC x 3-4 cycles then cystectomy) vs. cisplatin-ineligible (proceed to cystectomy). Post-cystectomy pathology assessment branches based on response: pT0/pT1 (surveillance) vs. high-risk residual disease (≥pT3/pN+) leading to adjuvant nivolumab. The perioperative immunotherapy pathway (neoadjuvant chemo+IO followed by adjuvant IO) is shown as an emerging option. Key trial names annotated at each decision point. Clinical algorithm format.</image>
<image>A bar chart comparing pathologic complete response (pT0) rates across major neoadjuvant regimens and combinations: GC alone (~25%), ddMVAC (~35-40%), pembrolizumab alone (~30-40% in PD-L1+), durvalumab + GC (NIAGARA), and other combinations. Each bar is labeled with the corresponding clinical trial name and patient population. A separate panel shows 5-year overall survival stratified by pathologic response: pT0, ≤pT1N0, and ≥pT2. Publication-quality comparison figure.</image>
Clinical Pearls
Cisplatin-based neoadjuvant chemotherapy confers a proven 5-6% absolute survival benefit and should be offered to all cisplatin-eligible patients with MIBC; however, it remains underutilized, representing a significant quality gap. Achieving pT0 status at cystectomy is the strongest prognostic factor, with patients who attain complete pathologic response experiencing over 85% 5-year survival. Carboplatin is not an acceptable substitute for cisplatin in the neoadjuvant setting; if a patient is cisplatin-ineligible, proceeding directly to cystectomy is preferred over administering an inferior regimen. Adjuvant nivolumab has become standard for patients with high-risk residual disease after cystectomy (≥pT3 or pN+), regardless of prior neoadjuvant chemotherapy. The NIAGARA trial is practice-changing, as perioperative durvalumab combined with GC is emerging as a new standard for cisplatin-eligible MIBC. Trimodal therapy offers a valid bladder-sparing alternative for highly selected patients but requires multidisciplinary discussion and is not appropriate for all MIBC cases. Finally, cystectomy should not be delayed beyond 12 weeks from diagnosis, as prolonged neoadjuvant treatment or surgical scheduling delays are associated with worse outcomes.
References
- Grossman HB, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer (SWOG 8710). N Engl J Med. 2003;349(9):859-866
- Advanced Bladder Cancer Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: updated systematic review and meta-analysis. J Clin Oncol. 2005;23(12):8529
- Bajorin DF, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma (CheckMate 274). N Engl J Med. 2021;384(22):2102-2114
- Powles T, et al. Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer (NIAGARA). N Engl J Med. 2024
- Giacalone NJ, et al. Long-term outcomes after bladder-preserving tri-modality therapy for MIBC. J Clin Oncol. 2017;35(30):3420-3429
- NCCN Clinical Practice Guidelines in Oncology: Bladder Cancer, Version 3.2024
